Search

Your search keyword '"C, Underhill"' showing total 224 results

Search Constraints

Start Over You searched for: Author "C, Underhill" Remove constraint Author: "C, Underhill"
224 results on '"C, Underhill"'

Search Results

102. Fishes of the Minnesota Region

103. Real-world impact of pembrolizumab availability for deficient mismatch repair metastatic colorectal cancer.

104. Stage-Specific Guideline Concordant Treatment Impacts on Survival in Nonsmall Cell Lung Cancer: A Novel Quality Indicator.

105. Pharmacogenetic-guided dosing for fluoropyrimidine (DPYD) and irinotecan (UGT1A1*28) chemotherapies for patients with cancer (PACIFIC-PGx): A multicenter clinical trial.

107. Telehealth in cancer care during the COVID-19 pandemic.

108. Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM).

109. Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.

110. Changing high-risk asthma in Memphis through partnership: Results from the CHAMP program.

111. Decentralized Clinical Trials as a New Paradigm of Trial Delivery to Improve Equity of Access.

112. A gut microbial signature for combination immune checkpoint blockade across cancer types.

113. Correction to: A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma.

114. A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma.

115. A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma.

116. Telehealth in oncology: a cost analysis to evaluate the financial impact of implementing regional trial hubs within a phase 3 cancer clinical trial.

117. Patient and healthcare professional acceptability of pharmacogenetic screening for DPYD and UGT1A1: A cross sectional survey.

118. Risk-Directed Ambulatory Thromboprophylaxis in Lung and Gastrointestinal Cancers: The TARGET-TP Randomized Clinical Trial.

120. Workforce challenges across Victorian medical oncology services.

123. SARS-CoV-2 Seroprevalence in a Cohort of International Travellers Returning to Rural Australia: Enablers and Barriers to Containment of COVID-19.

124. Teletrials, the new norm? Expert recommendations for teletrials into the future: Findings from the Clinical Oncology Society of Australia Clinical Trial Research Professionals Group Workshop.

125. Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers.

126. Pharmacogenomics guided dosing for fluoropyrimidine and irinotecan chemotherapies for patients with cancer (PACIFIC-PGx): study protocol of a multicentre clinical trial.

127. COVID-19 Vaccine Hesitancy in Australian Patients with Solid Organ Cancers.

128. Exploring Australian regional cancer patients' experiences of clinical trial participation via telehealth.

129. Serious Underlying Medical Conditions and COVID-19 Vaccine Hesitancy: A Large Cross-Sectional Analysis from Australia.

130. GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol).

131. CCTG BR34: A Randomized Phase 2 Trial of Durvalumab and Tremelimumab With or Without Platinum-Based Chemotherapy in Patients With Metastatic NSCLC.

132. Psychosocial well-being and supportive care needs of cancer patients and survivors living in rural or regional areas: a systematic review from 2010 to 2021.

133. Victorian Lung Cancer Service Redesign Project: impacts of a quality improvement collaborative on timeliness and management in lung cancer.

134. Medical Oncology Group of Australia position statement: COVID-19 vaccination in patients with solid tumours.

135. Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy.

136. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study.

137. Developing a Congregational Health Needs Assessment: Lessons Learned from Using a Participatory Research Approach.

138. Telehealth in cancer care: during and beyond the COVID-19 pandemic.

139. Towards new models of cancer care in Australia: lessons from Victoria's response to the COVID-19 pandemic.

140. Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers.

141. Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial.

142. Practical Considerations for Treating Patients With Cancer in the COVID-19 Pandemic.

143. Outpatient rituximab, ifosfamide, etoposide (R-IE) in patients older than 60 years with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for stem cell transplantation.

144. Gender differences in doxorubicin pharmacology for subjects with chemosensitive cancers of young adulthood.

145. Functional implications of corticosteroid-binding globulin N -glycosylation.

146. Switching to biosimilar infliximab: real world data in patients with severe inflammatory arthritis.

147. Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme.

148. Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study.

149. The impact of an inflammatory bowel disease nurse-led biologics service.

150. Guidelines for timely initiation of chemotherapy: a proposed framework for access to medical oncology and haematology cancer clinics and chemotherapy services.

Catalog

Books, media, physical & digital resources